HDAC6 and neoplasm: Moreover, HDAC6 inhibitors improve the therapeutic efficacy of anti-PD-1 immunotherapy by reducing the number of anti-inflammatory M1 macrophages and downregulating the expression of immune checkpoints such as PD-L1 in tumor cells [9].